Abstract

Research Article

Outcome of liver transplantation for autoimmune hepatitis in South Africa

Nida Mishraz Siddiqui*, Kapila Hari, Bilal Bobat, Dinen Parbhoo, Vikash Lala and Adam Mahomed

Published: 31 December, 2022 | Volume 6 - Issue 1 | Pages: 044-050

Background: Liver Transplantation (LT) is the definitive treatment for Autoimmune Hepatitis (AIH) in patients with decompensated cirrhosis, liver failure and hepatocellular carcinoma. Outcomes of LT in AIH among black-Africans are not well-defined. We performed a single-center retrospective-review of adult LT patients. The study period was from 1st August 2004-31st August 2019. The primary aim was to document 1- & 5- year patient and graft survival. A secondary aim was to compare the survival of black-Africans to Caucasians. Data was analyzed using survival-analysis. 
Results: A total of 56 LT were performed for AIH. Sixty-seven percent (n = 38/56) had confirmed AIH on explant histology. Of these, the majority i.e., 79% (30/38) were female and 21% (8/38) were male. There were equal numbers of black-African 42% (n = 16/38) and Caucasian 42% (n = 16/38) patients. Rejection was four-times higher in black-Africans as compared to Caucasians. Forty-four percent (n = 17/38) had an acute rejection episode and 13% (5/38) had chronic rejection. Recurrence was found in four black-African females. Post-LT patient survival at 1- and 5- years was 86.5% and 80.7%, and graft survival was 94% and 70.8% respectively. The 5- year patient survival was insignificantly lower for black-Africans (73.9%) as compared to Caucasians (83.7%) (p - value 0.26, CI 6.3 - 12.2). Five-year graft survival was significantly lower among black-Africans (55%) as compared to Caucasians (84.8%) (p - value 0.003 CI 3.8 - 8.1)
Conclusion: Black-Africans had a four-fold higher rate of rejection compared to Caucasians. Recurrent AIH was only found in patients of black ethnicity. Similar 1- & 5- year patient survival rates were observed between the two ethnicities. The 5-year graft survival among black-Africans was significantly lower than Caucasians.

Read Full Article HTML DOI: 10.29328/journal.acgh.1001038 Cite this Article Read Full Article PDF

Keywords:

Black Africans; Autoimmune hepatitis; Liver transplant; Rejection; Recurrence; Outcome

References

  1. Liberal R, Zen Y, Mieli-Vergani G, Vergani D. Liver transplantation and autoimmune liver diseases. Liver Transpl. 2013 Oct;19(10):1065-77. doi: 10.1002/lt.23704. Epub 2013 Aug 13. PMID: 23873751.
  2. Bernal RB, Medina-MoralesE, Goyes D. Management of autoimmune liver diseases after liver transplantation, Transplantology. 2021; 2:162-182.
  3. Taubert R, Hupa-Breier KL, Jaeckel E, Manns MP. Novel therapeutic targets in autoimmune hepatitis. J Autoimmun. 2018 Dec;95:34-46. doi: 10.1016/j.jaut.2018.10.022. Epub 2018 Nov 4. PMID: 30401504.
  4. Carbone M, Neuberger JM. Autoimmune liver disease, autoimmunity and liver transplantation. J Hepatol. 2014 Jan;60(1):210-23. doi: 10.1016/j.jhep.2013.09.020. Epub 2013 Sep 29. PMID: 24084655.
  5. Padilla M, Mayorga R, Carrasco F, Bedregal T, Bobadilla F, Rondón C, Chaman J. Liver transplantation for autoimmune hepatitis in Peru: outcomes and recurrence. Ann Hepatol. 2012 Mar-Apr;11(2):222-7. PMID: 22345339.
  6. Song E, Fabian J, Boshoff PE, Maher H, Gaylard P, Bentley A, Hale MJ, Ngwenya SP, Etheredge H, Mahomed A, Bobat B, Strobele B, Loveland J, Britz R, Botha JF. Adult liver transplantation in Johannesburg, South Africa (2004 - 2016): Balancing good outcomes, constrained resources and limited donors. S Afr Med J. 2018 Oct 26;108(11):929-936. doi: 10.7196/SAMJ.2018.v108i11.13286. PMID: 30645959.
  7. Krawitt EL. Autoimmune hepatitis. N Engl J Med. 2006 Jan 5;354(1):54-66. doi: 10.1056/NEJMra050408. PMID: 16394302.
  8. Sucher E, Sucher R, Gradistanac T, Brandacher G, Schneeberger S, Berg T. Autoimmune Hepatitis-Immunologically Triggered Liver Pathogenesis-Diagnostic and Therapeutic Strategies. J Immunol Res. 2019 Nov 25;2019:9437043. doi: 10.1155/2019/9437043. PMID: 31886312; PMCID: PMC6899271.
  9. Schneider JS, Montani M, Stickel F. Drug-Induced Autoimmune Hepatitis following Treatment with Zoledronic Acid. Case Rep Gastroenterol. 2017 Aug 8;11(2):440-445. doi: 10.1159/000479314. PMID: 29033761; PMCID: PMC5624238.
  10. Mubder M, Azab M, Jayaraj M, Cross C, Lankarani D, Dhindsa B, Pan JJ, Ohning G. Autoimmune hepatitis in patients with human immunodeficiency virus infection: A systematic review of the published literature. Medicine (Baltimore). 2019 Sep;98(37):e17094. doi: 10.1097/MD.0000000000017094. PMID: 31517833; PMCID: PMC6750342.
  11. Robinson MA, Nagurla SR, Noblitt TR, Almaghlouth NK, Al-Rahamneh MM, Cashin LM. Falsely positive fourth generation ADVIA Centaur® HIV Antigen/Antibody Combo assay in the presence of autoimmune hepatitis type I (AIH). IDCases. 2020 Jun 25;21:e00886. doi: 10.1016/j.idcr.2020.e00886. PMID: 32642434; PMCID: PMC7334457.
  12. Gleeson D. Long-Term Outcomes of Autoimmune Hepatitis. Clin Liver Dis (Hoboken). 2019 Aug 2;14(1):24-28. doi: 10.1002/cld.797. PMID: 31391933; PMCID: PMC6677096.
  13. Heinemann M, Adam R, Berenguer M, Mirza D, Malek-Hosseini SA, O'Grady JG, Lodge P, Pratschke J, Boudjema K, Paul A, Zieniewicz K, Fronek J, Weiss KH, Karam V, Duvoux C, Lohse A, Schramm C; all the other contributing centers (www.eltr.org) and the European Liver and Intestine Transplant Association (ELITA). Longterm Survival After Liver Transplantation for Autoimmune Hepatitis: Results From the European Liver Transplant Registry. Liver Transpl. 2020 Jul;26(7):866-877. doi: 10.1002/lt.25739. Epub 2020 May 1. PMID: 32112516.
  14. Vogel A, Heinrich E, Bahr MJ, Rifai K, Flemming P, Melter M, Klempnauer J, Nashan B, Manns MP, Strassburg CP. Long-term outcome of liver transplantation for autoimmune hepatitis. Clin Transplant. 2004 Feb;18(1):62-9. doi: 10.1111/j.1399-0012.2004.00117.x. PMID: 15108772.
  15. Lim KN, Casanova RL, Boyer TD, Bruno CJ. Autoimmune hepatitis in African Americans: presenting features and response to therapy. Am J Gastroenterol. 2001 Dec;96(12):3390-4. doi: 10.1111/j.1572-0241.2001.05272.x. PMID: 11774954.
  16. Thuluvath PJ, Wagennar RR, Verma S. Gender and ethnic differences in the post-liver transplant outcomes of patients with autoimmune hepatitis with acute liver failure at initial presentation: a case-control study. Arch Med Sci. 2015 Dec 10;11(6):1227-35. doi: 10.5114/aoms.2015.52736. Epub 2015 Dec 11. PMID: 26788084; PMCID: PMC4697044.
  17. Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, Vierling JM; American Association for the Study of Liver Diseases. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010 Jun;51(6):2193-213. doi: 10.1002/hep.23584. PMID: 20513004.
  18. Nair S, Eustace J, Thuluvath PJ. Effect of race on outcome of orthotopic liver transplantation: a cohort study. Lancet. 2002 Jan 26;359(9303):287-93. doi: 10.1016/S0140-6736(02)07494-9. PMID: 11830194.
  19. Lee BP, Dodge JL, Terrault NA. Changes and mediators of survival disparity among Black liver transplant recipients in the United States. Am J Transplant. 2021 Dec;21(12):3883-3893. doi: 10.1111/ajt.16767. Epub 2021 Aug 10. PMID: 34374495.
  20. Bayable A, Liu B, Bhuket T. 1001 significant differences in liver transplant (LT) waitlist mortality, receiving LT, and post-LT survival among adults with primary sclerosing cholangitis, primary biliary cholangitis, and autoimmune hepatitis in the U.S. Am J Gastroenterol. 2019; 114: S581.
  21. Wen JW, Kohn MA, Wong R, Somsouk M, Khalili M, Maher J, Tana MM. Hospitalizations for Autoimmune Hepatitis Disproportionately Affect Black and Latino Americans. Am J Gastroenterol. 2018 Feb;113(2):243-253. doi: 10.1038/ajg.2017.456. Epub 2018 Jan 30. PMID: 29380822; PMCID: PMC6522224.
  22. Rosenblatt R, Wahid N, Halazun KJ, Kaplan A, Jesudian A, Lucero C, Lee J, Dove L, Fox A, Verna E, Samstein B, Fortune BE, Brown RS Jr. Black Patients Have Unequal Access to Listing for Liver Transplantation in the United States. Hepatology. 2021 Sep;74(3):1523-1532. doi: 10.1002/hep.31837. PMID: 33779992.
  23. Nsubuga JP, Goyes D, Trivedi HD, Medina-Morales E, Patwardhan V, Bonder A. Waitlist Mortality and Posttransplant Outcomes in African Americans with Autoimmune Liver Diseases. J Transplant. 2021 Aug 3;2021:6692049. doi: 10.1155/2021/6692049. PMID: 34394979; PMCID: PMC8357471.
  24. Maggard M, Goss J, Ramdev S, Swenson K, Busuttil RW. Incidence of acute rejection in African-American liver transplant recipients. Transplant Proc. 1998 Jun;30(4):1492-4. doi: 10.1016/s0041-1345(98)00330-3. PMID: 9636607.
  25. Vasquez EM, Benedetti E, Pollak R. Ethnic differences in clinical response to corticosteroid treatment of acute renal allograft rejection. Transplantation. 2001 Jan 27;71(2):229-33. doi: 10.1097/00007890-200101270-00010. PMID: 11213064.
  26. Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev. 2002 Nov 18;54(10):1271-94. doi: 10.1016/s0169-409x(02)00066-2. PMID: 12406645.
  27. Nagashima N, Watanabe T, Nakamura M, Shalabi A, Burdick JF. Decreased effect of immunosuppression on immunocompetence in African--Americans after kidney and liver transplantation. Clin Transplant. 2001 Apr;15(2):111-5. doi: 10.1034/j.1399-0012.2001.150207.x. PMID: 11264637.
  28. Min DI, Lee M, Ku YM, Flanigan M. Gender-dependent racial difference in disposition of cyclosporine among healthy African American and white volunteers. Clin Pharmacol Ther. 2000 Nov;68(5):478-86. doi: 10.1067/mcp.2000.111255. PMID: 11103750.
  29. Isaacs RB, Nock SL, Spencer CE, Connors AF Jr, Wang XQ, Sawyer R, Lobo PI. Racial disparities in renal transplant outcomes. Am J Kidney Dis. 1999 Oct;34(4):706-12. doi: 10.1016/S0272-6386(99)70397-5. PMID: 10516353.
  30. Zahir H, McCaughan G, Gleeson M, Nand RA, McLachlan AJ. Factors affecting variability in distribution of tacrolimus in liver transplant recipients. Br J Clin Pharmacol. 2004 Mar;57(3):298-309. doi: 10.1046/j.1365-2125.2003.02008.x. PMID: 14998426; PMCID: PMC1884454.
  31. Montano-Loza AJ, Ronca V, Ebadi M, Hansen BE, Hirschfield G, Elwir S, Alsaed M, Milkiewicz P, Janik MK, Marschall HU, Burza MA, Efe C, Calışkan AR, Harputluoglu M, Kabaçam G, Terrabuio D, de Quadros Onofrio F, Selzner N, Bonder A, Parés A, Llovet L, Akyıldız M, Arikan C, Manns MP, Taubert R, Weber AL, Schiano TD, Haydel B, Czubkowski P, Socha P, Ołdak N, Akamatsu N, Tanaka A, Levy C, Martin EF, Goel A, Sedki M, Jankowska I, Ikegami T, Rodriguez M, Sterneck M, Weiler-Normann C, Schramm C, Donato MF, Lohse A, Andrade RJ, Patwardhan VR, van Hoek B, Biewenga M, Kremer AE, Ueda Y, Deneau M, Pedersen M, Mayo MJ, Floreani A, Burra P, Secchi MF, Beretta-Piccoli BT, Sciveres M, Maggiore G, Jafri SM, Debray D, Girard M, Lacaille F, Lytvyak E, Mason AL, Heneghan M, Oo YH; International Autoimmune Hepatitis Group (IAIHG). Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation. J Hepatol. 2022 Jul;77(1):84-97. doi: 10.1016/j.jhep.2022.01.022. Epub 2022 Feb 8. PMID: 35143897.
  32. Edmunds C, Ekong UD. Autoimmune Liver Disease Post-Liver Transplantation: A Summary and Proposed Areas for Future Research. Transplantation. 2016 Mar;100(3):515-24. doi: 10.1097/TP.0000000000000922. PMID: 26447505; PMCID: PMC4764021.
  33. Lammert C. Genetic and Environmental Risk Factors for Autoimmune Hepatitis. Clin Liver Dis (Hoboken). 2019 Aug 2;14(1):29-32. doi: 10.1002/cld.798. PMID: 31391934; PMCID: PMC6677013.
  34. Higuchi T, Oka S, Furukawa H, Tohma S, Yatsuhashi H, Migita K. Genetic risk factors for autoimmune hepatitis: implications for phenotypic heterogeneity and biomarkers for drug response. Hum Genomics. 2021 Jan 28;15(1):6. doi: 10.1186/s40246-020-00301-4. PMID: 33509297; PMCID: PMC7841991.
  35. Yoshizawa K, Ota M, Katsuyama Y, Ichijo T, Matsumoto A, Tanaka E, Kiyosawa K. Genetic analysis of the HLA region of Japanese patients with type 1 autoimmune hepatitis. J Hepatol. 2005 Apr;42(4):578-84. doi: 10.1016/j.jhep.2004.12.019. Epub 2005 Jan 21. PMID: 15763345.
  36. Bittencourt PL, Goldberg AC, Cançado EL, Porta G, Carrilho FJ, Farias AQ, Palacios SA, Chiarella JM, Abrantes-Lemos CP, Baggio VL, Laudanna AA, Kalil J. Genetic heterogeneity in susceptibility to autoimmune hepatitis types 1 and 2. Am J Gastroenterol. 1999 Jul;94(7):1906-13. doi: 10.1111/j.1572-0241.1999.01229.x. PMID: 10406258.
  37. Strettell MD, Donaldson PT, Thomson LJ, Santrach PJ, Moore SB, Czaja AJ, Williams R. Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis. Gastroenterology. 1997 Jun;112(6):2028-35. doi: 10.1053/gast.1997.v112.pm9178696. PMID: 9178696.
  38. Eskandari-Nasab E, Tahmasebi A, Hashemi M. Meta-analysis: the relationship between CTLA-4 +49 A/G polymorphism and primary biliary cirrhosis and type I autoimmune hepatitis. Immunol Invest. 2015;44(4):331-48. doi: 10.3109/08820139.2014.1003651. PMID: 25942345.
  39. Marais S. CTLA4 Gene Polymorphisms in Autoimmune Hepatitis (AIH): Gene and Clinical Disease Correlation in South African Patients. MSc (Med). University of Cape Town, Cape Town. 2007.

Figures:

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?